Top Markets
#1 Black Phoenix Black Phoenix +356.02%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.09%
#4 Akedo Akedo +49.04%
#5 Acurast Acurast +34.81%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.91%
#7 BasedHype BasedHype +25.95%
#8 Avantis Avantis +23.73%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.89%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Notable Labs, Ltd. Notable Labs, Ltd.

Notable Labs, Ltd.

NTBL
Rang in Aktien #41091
Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company,... Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug. The primary goal of the PPMP is to identify and qualify patients who are expected to respond favorably before they even begin treatment, thereby significantly accelerating the clinical development process for these specific patient groups. Notable Labs' current development pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor designed to treat acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes. Additionally, it features Fosciclopirox, a prodrug of ciclopirox, also aimed at acute myeloid leukemia. The company's headquarters are located in Foster City, California.
Aktienkurs
$0.0202
Zuletzt synchronisiert: 2024-11-19
Marktkapitalisierung
$44.67K
Veränderung (1 Tag)
-0.49%
Veränderung (1 Jahr)
0.00%
Land
IL
Handel Notable Labs, Ltd. (NTBL)

Kategorie

Healthcare
P/S-Verhältnis für Notable Labs, Ltd. (NTBL)
P/S-Verhältnis zum August 2026 TTM: 7.72
Laut den neuesten Finanzberichten und dem Aktienkurs von Notable Labs, Ltd. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 7.72. Am Ende des Jahres 2022 lag das P/S-Verhältnis bei 1.16K.
P/S-Verlauf für Notable Labs, Ltd. von 2015 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 7.72 -41.88%
2023 13.29 -98.86%
2022 1.16K -93.42%
2021 17.67K 387.47%
2020 3.63K -4.00%
2019 3.78K 97.37%
2018 1.91K 289.61%
2017 491.09 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 27.92%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 33.38%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -35.54%
BE